Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Chemomab Therapeutics Ltd. - American Depositary Shares (CMMB)
Company Research
Source: Yahoo! Finance
- - Cash Runway Extended to Early 2026 ; Continuing Discussions with Potential Strategic Partners Preparations Underway to Advance CM-101 to Phase 3 in Late 2025- - TEL AVIV, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the third quarter ended September 30, 2024, and provided a corporate update. “These are exciting and transformational times for Chemomab,” said Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab. "In the third quarter we reported the results of our CM-101 Phase 2 SPRING trial in patients with primary sclerosing cholangitis (PSC). The positive data from this trial represents a major clinical proof-of-concept for CM-101 as a potential disease-modifying treatment for PSC and other fibro-inflammatory
Show less
Read more
Impact Snapshot
Event Time:
CMMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMMB alerts
High impacting Chemomab Therapeutics Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CMMB
News
- Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit [Yahoo! Finance]Yahoo! Finance
- Chemomab to Participate in Oppenheimer’s Movers in Rare Disease SummitGlobeNewswire
- Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis [Yahoo! Finance]Yahoo! Finance
- Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing CholangitisGlobeNewswire
- Chemomab Therapeutics Ltd. (NASDAQ: CMMB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $11.00 price target on the stock, down previously from $13.00.MarketBeat
CMMB
Sec Filings
- 12/11/24 - Form EFFECT
- 12/2/24 - Form POS
- 11/29/24 - Form SC
- CMMB's page on the SEC website